Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia

Abstract

Fibroblast growth factor 23 (FGF23)–induced hypophosphatemia is a rare paraneoplastic syndrome of phosphate wasting that, if unrecognized, may cause tumor-induced osteomalacia. It is classically associated with benign mesenchymal tumors but occasionally has been found in patients with other malignancies. Hypophosphatemia has been associated with acute leukemia but has not previously been reported to be due to inappropriate FGF23 secretion. Here, we describe FGF23-induced severe hypophosphatemia and renal phosphate wasting associated with a mixed-phenotype Philadelphia chromosome-like acute leukemia in a previously healthy 22-year-old man. He was found to have low serum 1,25-dihydroxyvitamin D and extremely high FGF23 levels, as well as inappropriate urinary phosphorus excretion. The hypophosphatemia improved with calcitriol and oral phosphate treatment but normalized only during chemotherapy-induced ablation of the blasts. FGF23 levels declined with a reduction in peripheral blast counts. Using real-time reverse transcription polymerase chain reaction, we found that the leukemia cells were the source of FGF23. To our knowledge, this is the first description of FGF23-induced hypophosphatemia associated with acute leukemia. We recommend that the FGF23 paraneoplastic syndrome be considered as a possible etiology of hypophosphatemia in patients with acute leukemia.

Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature

“…PMTs are usually small, benign and characterised by low grade and mitotic index, requiring PET imaging to be detected [3]. However, it has also been linked with malignant haematological and solid tumours such as leukaemia [14], head and neck cancer [15], B cell non-Hodgkin's lymphoma [16], sarcoma [17], anaplastic thyroid carcinoma [18], small cell lung cancer [19], prostate cancer [20] and adenocarcinoma of the colon [21].…”

Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes

“…Similar to the mouse study, cFGF-23 rather than iFGF-23 may be critical for the interactions with RBC. Comparable increases of cFGF-23 levels were also found in acute myeloid leukemia (46) and in patients with chronic kidney disease and renal anemia (47), which in the latter also correlated negatively with hemoglobin values. Importantly, we collected a unique set of bone biopsies from MDS patients.…”

The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia

“…This case is the first report of a ZBTB20-JAK2 fusion defining a case of MLN-EGR presenting as B-ALL. Although remission following treatment of MLN-PJ with JAK2 inhibitors has been reported (Lierman et al 2012;Rumi et al 2013Rumi et al , 2015Bain and Ahmad 2014;Schwaab et al 2015;Reiter and Gotlib 2017), there is a near-complete absence of reported responses to these therapies targeting JAK mutations and/or fusion genes in B-ALLs, including Ph-like ALLs (Roberts et al 2014;Reinert et al 2018). This patient's case was appropriately initially classified as a B-ALL, and therapy was selected based on this diagnosis.…”